House appropriators offered several clinical trial diversity and reform directives to the US Food and Drug Administration as part of fiscal year 2022 budget legislation.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?